Self-emulsifying drug delivery systems (SEDDS): In vivo-proof of concept for oral delivery of insulin glargine.

Rats Animals Insulin Glargine Emulsions / chemistry Polysorbates Drug Delivery Systems / methods Peptides Administration, Oral
Hydrophobic ion pairing Insulin glargine Lipophilic counterions Oral peptide delivery Self-emulsifying drug delivery systems

Journal

International journal of pharmaceutics
ISSN: 1873-3476
Titre abrégé: Int J Pharm
Pays: Netherlands
ID NLM: 7804127

Informations de publication

Date de publication:
25 May 2023
Historique:
received: 20 03 2023
revised: 11 04 2023
accepted: 12 04 2023
medline: 12 5 2023
pubmed: 27 4 2023
entrez: 26 4 2023
Statut: ppublish

Résumé

In spite of recent progress made in the field of peptide and protein delivery, oral administration of insulin and similar drugs remains a challenge. In this study, lipophilicity of insulin glargine (IG) was successfully increased via hydrophobic ion pairing (HIP) with sodium octadecyl sulfate to enable incorporation into self-emulsifying drug delivery systems (SEDDS). Two SEDDS formulations (F1: 20% Labrasol®ALF, 30% polysorbate 80, 10% Croduret 50, 20% oleyl alcohol, 20% Maisine® CC; F2: 30% Labrasol®ALF, 20% polysorbate 80, 30% Kolliphor® HS 15, 20% Plurol® oleique CC 497) were developed and loaded with the IG-HIP complex. Further experiments confirmed increased lipophilicity of the complex, achieving LogD

Identifiants

DOI: 10.1016/j.ijpharm.2023.122964 PMID: 37100259
pubmed: 37100259
pii: S0378-5173(23)00384-8
doi: 10.1016/j.ijpharm.2023.122964
pii:
doi:

Substances chimiques

Insulin Glargine 2ZM8CX04RZ
Emulsions 0
Polysorbates 0
Peptides 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

122964

Informations de copyright

Copyright © 2023 The Author(s). Published by Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Andreas Bernkop-Schnuerch reports financial support was provided by Gattefossé SAS. Camille Dumont and Philippe Caisse report a relationship with Gattefossé SAS that includes: employment.

Auteurs

Victor Claus (V)

Department of Pharmaceutical Technology, University of Innsbruck, Institute of Pharmacy, Center for Chemistry and Biomedicine, 6020 Innsbruck, Austria; Thiomatrix Forschungs- und Beratungs GmbH, Trientlgasse 65, 6020 Innsbruck, Austria.

Helen Spleis (H)

Department of Pharmaceutical Technology, University of Innsbruck, Institute of Pharmacy, Center for Chemistry and Biomedicine, 6020 Innsbruck, Austria; Thiomatrix Forschungs- und Beratungs GmbH, Trientlgasse 65, 6020 Innsbruck, Austria.

Christoph Federer (C)

Thiomatrix Forschungs- und Beratungs GmbH, Trientlgasse 65, 6020 Innsbruck, Austria.

Katrin Zöller (K)

Department of Pharmaceutical Technology, University of Innsbruck, Institute of Pharmacy, Center for Chemistry and Biomedicine, 6020 Innsbruck, Austria.

Richard Wibel (R)

Department of Pharmaceutical Technology, University of Innsbruck, Institute of Pharmacy, Center for Chemistry and Biomedicine, 6020 Innsbruck, Austria.

Flavia Laffleur (F)

Department of Pharmaceutical Technology, University of Innsbruck, Institute of Pharmacy, Center for Chemistry and Biomedicine, 6020 Innsbruck, Austria.

Camille Dumont (C)

Gattefossé SAS, 36 Chemin de Genas, 69804 Saint-Priest Cedex, France.

Philippe Caisse (P)

Gattefossé SAS, 36 Chemin de Genas, 69804 Saint-Priest Cedex, France.

Andreas Bernkop-Schnürch (A)

Department of Pharmaceutical Technology, University of Innsbruck, Institute of Pharmacy, Center for Chemistry and Biomedicine, 6020 Innsbruck, Austria. Electronic address: Andreas.Bernkop@uibk.ac.at.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Evaluating the efficacy of telesurgery with dual console SSI Mantra Surgical Robotic System: experiment on animal model and clinical trials.

Sudhir Prem Srivastava, Vishwajyoti Pascual Srivastava, Avinesh Singh et al.
1.00
Robotic Surgical Procedures Animals Humans Telemedicine Models, Animal

Odour generalisation and detection dog training.

Lyn Caldicott, Thomas W Pike, Helen E Zulch et al.
1.00
Animals Odorants Dogs Generalization, Psychological Smell

FBXO22 inhibits colitis and colorectal carcinogenesis by regulating the degradation of the S2448-phosphorylated form of mTOR.

Minle Li, Xuan Chen, Pengfei Qu et al.
1.00
Animals TOR Serine-Threonine Kinases Colorectal Neoplasms Colitis Mice

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Rats › Self-emulsifying drug delivery systems...
questionsmedicales.fr › Eucaryotes › Animaux › Self-emulsifying drug delivery systems...
questionsmedicales.fr › Acides aminés, peptides et protéines › Peptides › Hormones peptidiques › Hormones pancréatiques › Insulines › Insuline à longue durée d'action › Insuline glargine › Self-emulsifying drug delivery systems...
questionsmedicales.fr › Préparations pharmaceutiques › Colloïdes › Émulsions › Self-emulsifying drug delivery systems...
questionsmedicales.fr › Technologie, industrie et agriculture › Produits manufacturés › Matériaux biomédicaux et dentaires › Polymères › Polyéthylène glycols › Polysorbates › Self-emulsifying drug delivery systems...
questionsmedicales.fr › Thérapeutique › Traitement médicamenteux › Systèmes de délivrance de médicaments › Self-emulsifying drug delivery systems...
questionsmedicales.fr › Acides aminés, peptides et protéines › Peptides › Self-emulsifying drug delivery systems...
questionsmedicales.fr › Thérapeutique › Traitement médicamenteux › Voies d'administration de substances chimiques et des médicaments › Administration par voie orale › Self-emulsifying drug delivery systems...